SIRPA and breast carcinoma: Similarly, the supramolecule blocking the CD47-SIRPα signaling axis while sustainably inhibiting CSF-1R enhanced M2 to M1 repolarization within the TME and significantly improved antitumor and antimetastatic efficacies in animal models of melanoma and breast cancer [46].